Press Releases

"Unfortunately, ludicrous demands from the chairman made it impossible for the attorney general to join us here today. . . . Over the 206-year history of this committee, staff have never questioned witnesses in such a hearing. Never. Not once. So, to say Chairman Nadler’s demands are unprecedented would be an understatement. . . . Chairman Nadler has stolen from all members and the Americans they represent the opportunity to exercise our oversight duties by questioning and hearing from the nation’s chief law enforcement officer. "

"This committee has heard how this bill would marginalize an almost endless spectrum of Americans, but I fear we have not listened. Today, as we recall who this bill will harm and how, I note it’s not too late to show courage. Everyone on this dais can listen sincerely, take heart and oppose legislation based in political theory, not scientific reality. If my Democrat colleagues do advance this misguided bill, they must admit this legislative win creates millions of losers. Intellectual honesty requires us to count the cost of H.R. 5."

"Democrats have ignored the reality of the Mueller investigation . . .  I implore you to stop bullying an attorney general who has conducted himself in an exemplary manner. Examine the report, ask earnest questions and heed the pleas of hardworking Americans who understand that our time is better spent making progress than chasing ghosts."

"Due to the lack of transparency, these price concessions are often withheld from patients and payers, increasing PBM profits while failing to decrease drug costs. H.R. 2376, the Prescription Pricing for the People Act of 2019, directs the FTC to review and report on PBMs' anticompetitive behaviors and other issues affecting competition in the pharmaceutical supply chain as a whole."